“…In our limited knowledge, stage may be the most importantly independent prognostic factors for all solid tumors. 2–5 In fact, the authors have clearly demonstrated the strong correlation between the high NLRP12 expression and advanced stage of intracranial glioma, suggesting that the expression of NLRP12 may depend on the tumor stage or vice versa.…”
“…In our limited knowledge, stage may be the most importantly independent prognostic factors for all solid tumors. 2–5 In fact, the authors have clearly demonstrated the strong correlation between the high NLRP12 expression and advanced stage of intracranial glioma, suggesting that the expression of NLRP12 may depend on the tumor stage or vice versa.…”
“…1 The spread of molecular pathology has paved the way for patient-tailored strategies, with the aim of improving short-and long-term outcomes. 6,7,9 Overall, we appreciate the authors' great work exploring the limitation of conventional clinicopathological parameters in the prediction of outcomes in GC patients who were treated with curative surgery. Surgery still represents the mainstay of treatment of all stages of GC, 6 similar to our experience in the management of uterine cancers.…”
Section: Dear Editormentioning
confidence: 99%
“…The optimal therapeutic goal of adjuvant therapy had better include the more confidence to the curative surgery, a better chance to minimize the damage to the surrounding tissue or systemic toxicity to human bodies, and subsequently, a higher quality of life after initial curative therapy. 7,8 Despite aforementioned questions, the authors' attempt to integrate the molecular pathology into the conventional clinicopathological parameters in the prediction of GC patients is worthy of encouragement. 1 The spread of molecular pathology has paved the way for patient-tailored strategies, with the aim of improving short-and long-term outcomes.…”
Section: Dear Editormentioning
confidence: 99%
“…The optimal therapeutic goal of adjuvant therapy had better include the more confidence to the curative surgery, a better chance to minimize the damage to the surrounding tissue or systemic toxicity to human bodies, and subsequently, a higher quality of life after initial curative therapy. 7,8…”
“…2 However, few patients with proposed curable diseases may recur later even though the initial primary active and curative treatment is given, and subsequently die of diseases, suggesting that an accurate and precise evaluation and appropriate and personalized therapeutic plan to those patients with supposedly curable diseases by far-advanced development of new technology or therapeutic strategy is critically important. 10,11 All efforts make the diseases with a maximal chance for curability. The article published in the January issue of the Journal of the Chinese Medical Association entitled “The clinicopathological and genetic differences among gastric cancer patients with no recurrence, early recurrence, and late recurrence after curative surgery” attempted to explore this topic, since the authors’ enrolled subjects belonged to complete resection of tumors and all of them received the curable surgery claimed by authors.…”
Malignant diseases are the main and leading cause of death in Taiwan, contributing to an urgent need of active care for patients with malignant diseases, regardless whether the earlyor late-stage of diseases are defined. [1][2][3] Cancer treatment can be simply grouped into two distinguished therapeutic approaches; one is the highly curative therapy applied either by surgery alone and/or radiation therapy with/without neoadjuvant therapy (NAT) or adjuvant therapy under multi-modality guidance; and the other is the palliative therapy or multidisciplinary decision-making with low possibility of curability, based on the characteristics and patterns of diseases at the initial diagnosis. [4][5][6][7][8][9] Except of some specific systemic diseases, patients with an in situ or organ-limited diseases have a better chance to be cured accompanied with a long-term survival after the initial primary curative treatment. 2 However, few patients with proposed curable diseases may recur later even though the initial primary active and curative treatment is given, and subsequently die of diseases, suggesting that an accurate and precise evaluation and appropriate and personalized therapeutic plan to those patients with supposedly curable diseases by far-advanced development of new technology or therapeutic strategy is critically important. 10,11 All efforts make the diseases with a maximal chance for curability. The article published in the January issue of the Journal of the Chinese Medical Association entitled "The clinicopathological and genetic differences among gastric cancer patients with no recurrence, early recurrence, and late recurrence after curative surgery" attempted to explore this topic, since the authors' enrolled subjects belonged to complete resection of tumors and all of them received the curable surgery claimed by authors. 12 The authors enrolled 473 patients with gastric cancer (GC) undergoing curative surgery to investigated the impact of genetic alterations and clinicopathological features on disease-free survival (DFS) and overall survival (OS) in these GC patients. 12 DFS was classified as no recurrence, early recurrence (defined by < 2 years) and late recurrence (defined by ≥ 2 years). 12 The authors found that PIK3CA amplifications in diffuse-type GC were associated with early recurrence and ARID1A mutations were frequently found in patients with single-site recurrence, suggesting that targeted therapy and immunotherapy might be helpful for these patients. 12 The current article is interesting and worthy of further discussion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.